Get started
Author

Ravi K. Jalluri

Observed names: R. Jalluri, R. K. JALLURI, R. K. Jalluri, Ravi Jalluri, Ravi K Jalluri
Observed institutions: University of Kansas, Universität Hamburg, University of Georgia, National Cancer Institute, Cogent Biosciences (United States), Celgene (United States), Incyte (United States)
ORCID: 0000-0003-4475-6304
Observed ORCID: 0000-0003-4475-6304
OpenAlex ID: A5002513171
2-Substituted paullones: CDK1/cyclin B-inhibiting property and in vitro antiproliferative activity
2000 · Conrad Kunick, Christiane Schultz, et al. · Bioorganic & Medicinal Chemistry Letters · 70
A Basis for New Approaches to the Chemotherapy of AIDS: Novel Genes in HIV-1 Potentially Encode Selenoproteins Expressed by Ribosomal Frameshifting and Termination Suppression
1994 · E. W. Taylor, C. S. Ramanathan, et al. · Journal of Medicinal Chemistry · 69
The Novel Bromodomain and Extraterminal Domain Inhibitor INCB054329 Induces Vulnerabilities in Myeloma Cells That Inform Rational Combination Strategies
2018 · Matthew C. Stubbs, Timothy C. Burn, et al. · Clinical Cancer Research · 51
Lead identification of a potent benzopyranone selective estrogen receptor modulator
2004 · Jeffrey A. McKie, Shripad S. Bhagwat, et al. · Bioorganic & Medicinal Chemistry Letters · 38
Discovery of a Potent, Selective, and Orally Active Human Epidermal Growth Factor Receptor-2 Sheddase Inhibitor for the Treatment of Cancer
2007 · Wenqing Yao, Jincong Zhuo, et al. · Journal of Medicinal Chemistry · 35
Synthesis, Biochemical Evaluation, and Classical and Three-Dimensional Quantitative Structure−Activity Relationship Studies of 7-Substituted-1,2,3,4-tetrahydroisoquinolines and Their Relative Affinities toward Phenylethanolamine N-Methyltransferase and the α2-Adrenoceptor,1
1998 · Gary L. Grunewald, Vilas H. Dahanukar, et al. · Journal of Medicinal Chemistry · 24
Relative stereochemistry and solution conformation of the novel paclitaxel-like antimitotic agent epothilone A
1996 · Sam F. Victory, David G. Vander Velde, et al. · Bioorganic & Medicinal Chemistry Letters · 20
Discovery of Orally Bioavailable FGFR2/FGFR3 Dual Inhibitors via Structure-Guided Scaffold Repurposing Approach
2023 · Minh H. Nguyen, Hai-Fen Ye, et al. · ACS Medicinal Chemistry Letters · 18
PDF
Comparative molecular field analysis (CoMFA) models of phenylethanolamine N-methyltransferase (PNMT) and the α2-adrenoceptor: The development of new, highly selective inhibitors of PNMT
1999 · Gary L. Grunewald, Timothy M. Caldwell, et al. · Bioorganic & Medicinal Chemistry Letters · 15
Discovery of 1'-(1-phenylcyclopropane-carbonyl)-3H-spiro[isobenzofuran-1,3'-pyrrolidin]-3-one as a novel steroid mimetic scaffold for the potent and tissue-specific inhibition of 11β-HSD1 using a scaffold-hopping approach
2022 · Colin Zhang, Meizhong Xu, et al. · Bioorganic & Medicinal Chemistry Letters · 13
O—C—N Anomeric Effect in Nucleosides: A Major Factor Underlying the Experimentally Observed Eastern Barrier to Pseudorotation
1993 · Ravi K. Jalluri, Young H. Yuh, et al. · ACS symposium series · 12
The chemistry of the taxane diterpene: Stereoselective synthesis of 10-deacetoxy-11,12-epoxypaclitaxel
1995 · Geraldine C.B. Harriman, Ravi K. Jalluri, et al. · Tetrahedron Letters · 10
DNA Polymerase Photoprobe 2-[(4-Azidophenacyl)thio]-2‘-deoxyadenosine 5‘-Triphosphate Labels an Escherichia coli DNA Polymerase I Klenow Fragment Substrate Binding Site,
1996 · Bob M. Moore, Ravi K. Jalluri, et al. · Biochemistry · 9
Discovery of INCB126503 as a Potent and Selective FGFR2/3 Inhibitor
2025 · Minh H. Nguyen, Anlai Wang, et al. · ACS Medicinal Chemistry Letters · 7
PDF
A New Synthesis of the Potent 5-HT1Receptor Ligand, 5-Carboxyamidotryptamine (5-CT)
1993 · Atul Agarwal, R. K. Jalluri, et al. · Synthetic Communications · 7
Discovery of a Novel 2-Spiro-Proline Steroid Mimetic Scaffold for the Potent Inhibition of 11β-Hsd1
2022 · David M. Burns, Chunhong He, et al. · Bioorganic & Medicinal Chemistry Letters · 4
Discovery of the Orally Bioavailable Isoform Selective Janus Kinase 1 (JAK1) Compound Povorcitinib (INCB054707) for the Treatment of Inflammatory and Autoimmune Diseases
2026 · Jincong Zhuo, Yun-Long Li, et al. · Journal of Medicinal Chemistry · 3
Abstract 4729: The reversible and selective FGFR2/3 inhibitor CGT4859 has superior target coverage of resistance mutations missed by leading FGFR inhibitors
2025 · John Fischer, Karyn Bouhana, et al. · Cancer Research · 2
Abstract 5623: Identification of CGT4255 an EGFR sparing, pan-mutant HER2 clinical development candidate with potential best-in-class brain penetration
2025 · Mark J. Chicarelli, Tanna Bettendorf, et al. · Cancer Research · 1
Abstract 3004: Preclinical characterization of CGT6297, a novel PI3Kα H1047R mutant-selective inhibitor
2025 · Aaron C. Smith, Ben Arwood-Levine, et al. · Cancer Research · 1
MPN-1139: Bezuclastinib Expanded Access Program for Patients With Systemic Mastocytosis
2026 · Lindsay Rein, Ali Malinowski, et al. · Clinical Lymphoma Myeloma & Leukemia
Abstract 410: Characterization of CGT1263, a KRAS (ON/OFF) inhibitor clinical candidate with selectivity for mutant KRAS over HRAS and NRAS.
2026 · John Fischer, Kim Alley, et al. · Cancer Research
Abstract 5869: Preclinical characterization of CGT4255, an EGFR sparing, pan-mutant HER2 clinical development candidate with potential best-in-class brain penetration
2026 · Paul Larsen, Tanna Bettendorf, et al. · Cancer Research
Preclinical characterization of a novel, wild-type-sparing, JAK2 V617F mutant-selective inhibitor
2025 · Mark Chicarelli, Michelle Crow, et al. · Blood
PDF
Abstract B024: Identification of a potent KRAS (ON) inhibitor clinical candidate series with selectivity for mutant KRAS over HRAS and NRAS
2025 · John Fischer, Kim Alley, et al. · Molecular Cancer Therapeutics
Works count: 50
Citation count: 409
H-index: 11
I10-index: 12
Year
Topic
Type